MRNA
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Moderna, Inc.
- Nom
- Moderna, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $79.7B
- Employés
- 4,700
- PDG
- Stéphane Bancel
- Site web
- https://www.modernatx.com
- Marché
- ARCTBNTXGSKINONVAXOGEN
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 499 246 titres (~28 062 617,66 $ US)
- Insiders
- Bancel Stephane
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$33,927,305
Avg sell (VWAP, 90d window) $104.17 vs last close $198.85 (+90.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$33,927,305 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-05
- Liquidity
- Liquid $3,982,241,736/day · 20d vol
- Last synced
-
2026-10-27 02:49:12
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Hoge Stephen | Sell · S · 10b5-1 | 39,145 | $220.72 | $8,640,084 | Form 4 |
| 2026-10-14 | Hoge Stephen | Sell · S · 10b5-1 | 450 | $214.15 | $96,368 | Form 4 |
| 2026-09-15 | Hoge Stephen | Sell · S · 10b5-1 | 40,281 | $146.07 | $5,883,846 | Form 4 |
| 2026-09-14 | Hoge Stephen | Sell · S · 10b5-1 | 40,294 | $144.13 | $5,807,574 | Form 4 |
| 2026-09-10 | Mock James M | Sell · S · 10b5-1 | 15,000 | $134.49 | $2,017,350 | Form 4 |
| 2026-09-01 | Klinger Shannon Thyme | Sell · S · 10b5-1 | 3,471 | $139.95 | $485,766 | Form 4 |
| 2026-08-05 | Bancel Stephane | Sell · S · 10b5-1 | 187,044 | $58.79 | $10,996,317 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-09-11 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-09-04 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-08-19 | Maria Elvira Salazar | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar | Sale | $1,001 - $15,000 |
| 2026-09-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-09-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-08-19 | Maria Elvira Salazar | Sale | $1,001 - $15,000 |
| 2026-08-19 | Maria Elvira Salazar | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-07-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-25 | Robert P. Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-01 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-15 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $50,001 - $100,000 |
| 2023-06-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Purchase | $50,001 - $100,000 |
| 2023-03-31 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Full) | $50,001 - $100,000 |
| 2023-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-11-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-03-16 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-07-22 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-03-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-01-29 | Marie Newman | Sale (Full) | $15,001 - $50,000 |
| 2021-01-29 | Marie Newman | Sale (Full) | $1,001 - $15,000 |
| 2020-05-22 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Moderna's strong cash position (liquidity score 75) is the sole bright spot, but deeply negative operating margins, persistent cash burn, and a collapsing revenue base make the fundamental outlook (score 15) extremely…
The first sentence of the analysis written for MRNA on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $11.0M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $11.0M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 3.29 · operating margin -158% — readings disagree
Suggested stop 118.77, nearest stored support minus 0.5 ATR(40.3% under the last close). Research, not advice. Not an order.
Recent news
- 2026-10-26 Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT? FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
- 2026-10-26 Moderna''s Rally May Have Run Out of Steam. Here''s What to Watch Next Moderna''s stock has taken a big hit that could signal the end of this year''s cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
- 2026-10-26 Data about Merck and Moderna Melanoma Vaccine Leaks Out Leaked data from Moderna and Merck''s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people''s lives and forming the same conclusion.
- 2026-10-26 The excitement around Moderna''s cancer vaccine is cooling. Here''s why. Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker''s experimental cancer treatment.
- 2026-10-26 Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.
- 2026-10-26 Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing Moderna Inc. (NASDAQ:MRNA) investors spent months treating the company''s cancer vaccine as a potential cure. Last week, leaked trial data delivered a reality check.
- 2026-10-26 Breakfast News: Science Strikes Back at Cancer Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
- 2026-10-24 Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript
- 2026-10-24 Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial Moderna NASDAQ: MRNA presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck''s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of distant metastasis-free survival, according to lead investigator Georgina Long of Melanoma Institute Australia.
- 2026-10-24 Breakfast News: A Conversation With Moderna''s CEO This August, Moderna (MRNA -1.25%) and Merck (MRK -1.34%) reported that their personalized cancer vaccine, intismeran autogene, cut the risk of melanoma recurrence after surgery when added to Keytruda. The result came from a phase 3 trial, the large final-stage study regulators lean on for approval.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 55.3% | 54.2% | 31.5% | 71.3% | 85.2% | |
| Ebit Margin | -142.4% | -112.0% | -57.0% | 50.9% | 75.0% | |
| Ebitda Margin | -131.3% | -106.1% | -47.9% | 52.7% | 76.3% | |
| Operating Profit Margin | -158.1% | -123.3% | -61.9% | 49.9% | 75.0% | |
| Pretax Profit Margin | -142.4% | -112.8% | -57.6% | 50.7% | 74.9% | |
| Continuous Operations Profit Margin | -145.2% | -111.3% | -68.8% | 44.3% | 68.8% | |
| Net Profit Margin | -145.2% | -111.3% | -68.8% | 44.3% | 68.8% | |
| Bottom Line Profit Margin | -145.2% | -111.3% | -68.8% | 44.3% | 68.8% | |
| Current Ratio | 3.293 | 3.671 | 3.425 | 2.728 | 1.761 | |
| Quick Ratio | 3.216 | 3.618 | 3.358 | 2.535 | 1.603 | |
| Solvency Ratio | -0.707 | -1.040 | -0.895 | 1.293 | 1.181 | |
| Cash Ratio | 1.306 | 0.874 | 0.964 | 0.651 | 0.750 | |
| Price To Earnings Ratio | -4.062 | -4.485 | -8.059 | 8.449 | 8.379 | |
| Price To Earnings Growth Ratio | 0.187 | 0.180 | 0.051 | -0.283 | -0.005 | |
| Forward Price To Earnings Growth Ratio | 0.187 | 0.180 | 0.051 | -0.283 | -0.005 | |
| Price To Earnings Diluted Ratio | -4.062 | -4.485 | -8.059 | 8.936 | 8.978 | |
| Price To Earnings Diluted Growth Ratio | 0.187 | 0.180 | 0.050 | -0.309 | -0.006 | |
| Price To Book Ratio | 1.326 | 1.465 | 2.742 | 3.701 | 7.236 | |
| Price To Sales Ratio | 5.901 | 4.991 | 5.548 | 3.749 | 5.771 | |
| Price To Free Cash Flow Ratio | -5.555 | -3.938 | -9.932 | 15.449 | 7.675 | |
| Price To Operating Cash Flow Ratio | -6.125 | -5.315 | -12.184 | 14.208 | 7.515 | |
| Debt To Assets Ratio | 0.155 | 0.053 | 0.067 | 0.046 | 0.037 | |
| Debt To Equity Ratio | 0.222 | 0.069 | 0.090 | 0.063 | 0.065 | |
| Debt To Capital Ratio | 0.181 | 0.064 | 0.082 | 0.059 | 0.061 | |
| Long Term Debt To Capital Ratio | 0.126 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.426 | 1.297 | 1.330 | 1.352 | 1.744 | |
| Working Capital Turnover Ratio | 0.372 | 0.485 | 0.866 | 2.443 | 4.007 | |
| Operating Cash Flow Ratio | -0.943 | -1.362 | -1.034 | 1.012 | 1.492 | |
| Operating Cash Flow Sales Ratio | -0.963 | -0.939 | -0.455 | 0.264 | 0.768 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | 1.350 | 1.227 | 0.920 | 0.979 | |
| Debt Service Coverage Ratio | -260.700 | -139.500 | -106.711 | 301.345 | 691.778 | |
| Interest Coverage Ratio | -307.400 | -164.375 | -111.553 | 324.828 | 738.667 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.978 | -4.021 | -2.508 | 4.151 | 14.869 | |
| Capital Expenditure Coverage Ratio | -9.755 | -2.858 | -4.410 | 12.453 | 47.958 | |
| Dividend Paid And Capex Coverage Ratio | -9.755 | -2.858 | -4.410 | 12.453 | 47.958 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.227 | -4.357 | -11.065 | 6.910 | 7.124 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 55.4% | ▲1.1% | ▼-4.2% |
| Ebit Margin | -142.4% | ▼-30.4% | ▼-105.3% |
| Ebitda Margin | -131.3% | ▼-25.2% | ▼-100.1% |
| Operating Profit Margin | -158.1% | ▼-34.8% | ▼-114.4% |
| Pretax Profit Margin | -142.4% | ▼-29.6% | ▼-105.0% |
| Continuous Operations Profit Margin | -145.2% | ▼-33.9% | ▼-102.7% |
| Net Profit Margin | -145.2% | ▼-33.9% | ▼-102.7% |
| Bottom Line Profit Margin | -145.2% | ▼-33.9% | ▼-102.7% |
| Current Ratio | 3.293 | ▼-0.378 | ▲0.318 |
| Quick Ratio | 3.216 | ▼-0.402 | ▲0.350 |
| Solvency Ratio | -0.707 | ▲0.334 | ▼-0.673 |
| Cash Ratio | 1.306 | ▲0.432 | ▲0.397 |
| Price To Earnings Ratio | -4.062 | ▲0.423 | ▼-4.106 |
| Price To Earnings Growth Ratio | 0.187 | ▲0.007 | ▲0.161 |
| Forward Price To Earnings Growth Ratio | 0.187 | ▲0.007 | ▲0.161 |
| Price To Earnings Diluted Ratio | -4.062 | ▲0.423 | ▼-4.324 |
| Price To Earnings Diluted Growth Ratio | 0.187 | ▲0.007 | ▲0.167 |
| Price To Book Ratio | 1.326 | ▼-0.139 | ▼-1.968 |
| Price To Sales Ratio | 5.901 | ▲0.910 | ▲0.709 |
| Price To Free Cash Flow Ratio | -5.555 | ▼-1.618 | ▼-6.295 |
| Price To Operating Cash Flow Ratio | -6.125 | ▼-0.810 | ▼-5.745 |
| Debt To Assets Ratio | 0.155 | ▲0.102 | ▲0.084 |
| Debt To Equity Ratio | 0.222 | ▲0.153 | ▲0.120 |
| Debt To Capital Ratio | 0.181 | ▲0.117 | ▲0.092 |
| Long Term Debt To Capital Ratio | 0.126 | ▲0.126 | ▲0.101 |
| Financial Leverage Ratio | 1.426 | ▲0.129 | ▼-0.004 |
| Working Capital Turnover Ratio | 0.372 | ▼-0.113 | ▼-1.262 |
| Operating Cash Flow Ratio | -0.943 | ▲0.419 | ▼-0.776 |
| Operating Cash Flow Sales Ratio | -0.964 | ▼-0.024 | ▼-0.698 |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | ▼-0.247 | ▼-0.013 |
| Debt Service Coverage Ratio | -260.700 | ▼-121.200 | ▼-357.942 |
| Interest Coverage Ratio | -307.400 | ▼-143.025 | ▼-403.433 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.978 | ▲3.044 | ▼-3.280 |
| Capital Expenditure Coverage Ratio | -9.755 | ▼-6.897 | ▼-18.433 |
| Dividend Paid And Capex Coverage Ratio | -9.755 | ▼-6.897 | ▼-18.433 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.227 | ▲0.129 | ▼-3.104 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.47B | $15.97B | $37.99B | $70.77B | $102.35B | |
| Enterprise value | $10.79B | $14.79B | $36.33B | $68.77B | $96.42B | |
| EV / Sales | 5.55x | 4.62x | 5.30x | 3.64x | 5.44x | |
| EV / Op. cash flow | -5.76x | -4.92x | -11.65x | 13.81x | 7.08x | |
| EV / Free cash flow | -5.23x | -3.65x | -9.50x | 15.01x | 7.23x | |
| EV / EBITDA | -4.23x | -4.36x | -11.06x | 6.91x | 7.12x | |
| Net debt / EBITDA | 0.27x | 0.35x | 0.51x | -0.20x | -0.44x | |
| Current ratio | 3.29x | 3.67x | 3.42x | 2.73x | 1.76x | |
| Income quality | 0.66x | 0.84x | 0.66x | 0.60x | 1.12x | |
| Graham number | — | — | — | $152 | $155 | |
| Graham net-net | $6 | $11 | $13 | $12 | $8 | |
| Tax burden | 102.0% | 98.7% | 119.6% | 87.3% | 91.8% | |
| Interest burden | 100.0% | 100.7% | 101.0% | 99.7% | 99.9% | |
| Working capital | $4.56B | $5.89B | $7.31B | $8.51B | $6.94B | |
| Invested capital | $7.51B | $8.94B | $10.06B | $10.65B | $8.33B | |
| Return on assets | -22.9% | -25.2% | -25.6% | 32.3% | 49.5% | |
| Operating ROA | -23.2% | -24.2% | -19.1% | 37.3% | 83.1% | |
| Return on tangible assets | -23.1% | -25.3% | -25.7% | 32.3% | 49.5% | |
| Return on equity | -32.6% | -32.7% | -34.0% | 43.7% | 86.3% | |
| Return on invested capital | -29.7% | -32.5% | -27.5% | 38.9% | 77.5% | |
| Return on capital employed | -29.7% | -33.1% | -27.5% | 45.0% | 85.6% | |
| Earnings yield | -24.6% | -22.3% | -12.4% | 11.8% | 11.9% | |
| Free cash flow yield | -18.0% | -25.4% | -10.1% | 6.5% | 13.0% | |
| Capex / Op. cash flow | -10.3% | -35.0% | -22.7% | 8.0% | 2.1% | |
| Capex / Depreciation | 89.3% | 556.1% | 113.8% | 114.9% | 122.4% | |
| Capex / Sales | 9.9% | 32.9% | 10.3% | 2.1% | 1.6% | |
| SG&A / Sales | 52.4% | 36.7% | 22.6% | 6.0% | 3.2% | |
| R&D / Sales | 161.1% | 142.0% | 70.8% | 17.5% | 11.2% | |
| Stock comp / Sales | 24.8% | 13.4% | 4.5% | 1.2% | 0.8% | |
| Intangibles / Total assets | 0.8% | 0.7% | 0.5% | 0.0% | 0.0% | |
| Days sales outstanding | 53d | 68d | 58d | 33d | 68d | |
| Days payables outstanding | 133d | 101d | 40d | 33d | 42d | |
| Operating cycle | 118d | 97d | 73d | 97d | 269d | |
| Cash conversion cycle | -16d | -4d | 33d | 64d | 227d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years